Nadine Hertel

Ratzeburger Allee 160
Luebeck, SH 23538, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Primary refractory plasmablastic lymphoma: A precision oncology approach.

Primary refractory plasmablastic lymphoma: A precision oncology approach.

Journal: Frontiers in oncology

Published: December 21, 2022

Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China.

Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China.

Journal: PharmacoEconomics - open

Published: December 04, 2022

Cost-effectiveness of nivolumab in patients with NSCLC in the United States.

Cost-effectiveness of nivolumab in patients with NSCLC in the United States.

Journal: The American journal of managed care

Published: August 30, 2021

Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways.

Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways.

Journal: Blood advances

Published: June 09, 2021

Non-Price-Related Determinants of Value and Access for Novel Non-small Cell Lung Cancer Treatments: A Cross-Country Review of HTA Decision Making.

Non-Price-Related Determinants of Value and Access for Novel Non-small Cell Lung Cancer Treatments: A Cross-Country Review of HTA Decision Making.

Journal: PharmacoEconomics - open

Published: June 05, 2021

Performance of international prognostic indices in plasmablastic lymphoma: a comparative evaluation.

Performance of international prognostic indices in plasmablastic lymphoma: a comparative evaluation.

Journal: Journal of cancer research and clinical oncology

Published: November 28, 2020

Clinicopathological characteristics and MYC status determine treatment outcome in plasmablastic lymphoma: a multi-center study of 76 consecutive patients.

Clinicopathological characteristics and MYC status determine treatment outcome in plasmablastic lymphoma: a multi-center study of 76 consecutive patients.

Journal: Blood cancer journal

Published: March 18, 2020

Costs and Cost Drivers Associated with Non-Small-Cell Lung Cancer Patients Who Received Two or More Lines of Therapy in Europe.

Costs and Cost Drivers Associated with Non-Small-Cell Lung Cancer Patients Who Received Two or More Lines of Therapy in Europe.

Journal: ClinicoEconomics and outcomes research : CEOR

Published: July 18, 2019

The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictions.

The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictions.

Journal: Population health metrics

Published: September 12, 2017

An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?

An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?

Journal: Health policy (Amsterdam, Netherlands)

Published: August 01, 2017

The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England.

The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England.

Journal: The European journal of health economics : HEPAC : health economics in prevention and care

Published: June 14, 2017

The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Evaluation Due to Failing to Account for the Distribution of Patient Weight.

The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Evaluation Due to Failing to Account for the Distribution of Patient Weight.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: September 30, 2015

Showing 1-12 of 15

Last Updated: 09/26/2026